Regular Article
Gastric Inhibitory Polypeptide Activates MAP Kinase through the Wortmannin-Sensitive and -Insensitive Pathways

https://doi.org/10.1006/bbrc.1997.6743Get rights and content

Abstract

The signal transduction pathways of a cloned human gastric inhibitory polypeptide (GIP) receptor have been investigated in CHO cells stably expressing this receptor. Exposure of GIP receptor expressing cells to GIP significantly increased MAP kinase activity. Time course analysis showed that a rapid and marked increase in MAP kinase activation was detected and that this activation reached maximal levels 10 min after the addition of GIP. Dose-response analysis showed that GIP activated MAP kinase activity in a dose-dependent manner with an ED50value of 5.9 × 10−10M of GIP. Wortmannin, a potent inhibitor of phosphatidylinositol 3-kinase (PI3-kinase), partially inhibited GIP-induced MAP kinase activation, suggesting that GIP activates MAP kinase through two different, wortmannin-sensitive and -insensitive pathways. It has been demonstrated that in CHO cells cAMP attenuates MAP kinase activity by inhibiting Raf-1. Since GIP elevates intracellular cAMP, we examined the effects of cAMP on MAP kinase activation. Interestingly, forskolin, which increased intracellular cAMP levels, significantly inhibited MAP kinase activation by GIP, but did not affect MAP kinase activation by GIP in the presence of wortmannin, suggesting that the wortmannin-sensitive pathway activates an MAP kinase cascade at or above the level of Raf-1 and that the wortmannin-insensitive pathway activates an MAP kinase cascade below the level of Raf-1. These findings demonstrate that the GIP receptor is linked to the MAP kinase cascade via at least two different pathways.

References (38)

  • A.J. Moody et al.

    FEBS Lett.

    (1984)
  • K. Yasuda et al.

    Biochem. Biophys. Res. Commun.

    (1994)
  • B. Amiranoff et al.

    Biochem. Biophys. Res. Commun.

    (1984)
  • M.A. Wahl et al.

    Mol. Cell. Endocrinol.

    (1992)
  • Y. Yamada et al.

    Genomics

    (1995)
  • T.G. Boulton et al.

    Cell

    (1991)
  • R.J. Davis

    J. Biol. Chem.

    (1993)
  • K.J. Blumer et al.

    Trends. Biochem. Sci.

    (1994)
  • M. Frödin et al.

    J. Biol. Chem.

    (1995)
  • S.G. Straub et al.

    Biochem. Biophys. Res. Commun.

    (1996)
  • S.G. Straub et al.

    J. Biol. Chem.

    (1996)
  • A. Kubota et al.

    Biochem. Biophys. Res. Commun.

    (1994)
  • H. Yano et al.

    J. Biol. Chem.

    (1993)
  • L.L. Lin et al.

    Cell

    (1993)
  • Z.I. Honda et al.

    J. Biol. Chem.

    (1994)
  • C. Sakanaka et al.

    Biochem. Biophys. Res. Commun.

    (1994)
  • M. Frödin et al.

    J. Biol. Chem.

    (1994)
  • T.S. Chao et al.

    J. Biol. Chem.

    (1994)
  • Cited by (41)

    • Naturally occurring mutations in G protein-coupled receptors associated with obesity and type 2 diabetes mellitus

      2022, Pharmacology and Therapeutics
      Citation Excerpt :

      GIPR primarily activates cAMP signaling and shows high constitutive cAMP activity (Fortin et al., 2010). Moreover, GIPR also activates MAPK pathway (Kubota et al., 1997) and phosphatidylinositol 3-kinase/protein kinase B pathway (Trumper et al., 2001). In addition, the GIPR has been shown to undergo homologous desensitization, in which β-arrestin 1 and G protein-coupled receptor kinase are implicated (Tseng & Zhang, 1998, 2000).

    • GIP

      2013, Handbook of Biologically Active Peptides
    • Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and β cell preservation

      2011, Progress in Biophysics and Molecular Biology
      Citation Excerpt :

      Later, proliferative effects were also demonstrated of GIPR activation in INS-1 cells (Bocker and Verspohl, 2001; Trumper et al., 2001). It has been shown that GIP activates the Raf-Mek1/2-ERK1/2 signaling module through cAMP/PKA signaling in GIPR-overexpressing CHO cells (Trumper et al., 2001; Ehses et al., 2002; Kubota et al., 1997) (Fig. 5). Consistent with these observations, PKA and MEK inhibitors have been shown to prevent GIP-induced proliferation of cultured islet cells (Friedrichsen et al., 2006).

    View all citing articles on Scopus
    View full text